157 related articles for article (PubMed ID: 37555901)
21. Gastrin-releasing peptide receptor-based targeting using bombesin analogues is superior to metabolism-based targeting using choline for in vivo imaging of human prostate cancer xenografts.
Schroeder RP; van Weerden WM; Krenning EP; Bangma CH; Berndsen S; Grievink-de Ligt CH; Groen HC; Reneman S; de Blois E; Breeman WA; de Jong M
Eur J Nucl Med Mol Imaging; 2011 Jul; 38(7):1257-66. PubMed ID: 21431398
[TBL] [Abstract][Full Text] [Related]
22.
von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
[TBL] [Abstract][Full Text] [Related]
23. Correlation of
Duan H; Baratto L; Fan RE; Soerensen SJC; Liang T; Chung BI; Thong AEC; Gill H; Kunder C; Stoyanova T; Rusu M; Loening AM; Ghanouni P; Davidzon GA; Moradi F; Sonn GA; Iagaru A
J Nucl Med; 2022 Dec; 63(12):1829-1835. PubMed ID: 35552245
[No Abstract] [Full Text] [Related]
24. Preclinical comparison of Al18F- and 68Ga-labeled gastrin-releasing peptide receptor antagonists for PET imaging of prostate cancer.
Chatalic KL; Franssen GM; van Weerden WM; McBride WJ; Laverman P; de Blois E; Hajjaj B; Brunel L; Goldenberg DM; Fehrentz JA; Martinez J; Boerman OC; de Jong M
J Nucl Med; 2014 Dec; 55(12):2050-6. PubMed ID: 25413139
[TBL] [Abstract][Full Text] [Related]
25. A new (68)Ga-labeled BBN peptide with a hydrophilic linker for GRPR-targeted tumor imaging.
Pan D; Xu YP; Yang RH; Wang L; Chen F; Luo S; Yang M; Yan Y
Amino Acids; 2014 Jun; 46(6):1481-9. PubMed ID: 24633452
[TBL] [Abstract][Full Text] [Related]
26. PET Probes for Preclinical Imaging of GRPR-Positive Prostate Cancer: Comparative Preclinical Study of [
Kálmán-Szabó I; Szabó JP; Arató V; Dénes N; Opposits G; Jószai I; Kertész I; Képes Z; Fekete A; Szikra D; Hajdu I; Trencsényi G
Int J Mol Sci; 2022 Sep; 23(17):. PubMed ID: 36077458
[TBL] [Abstract][Full Text] [Related]
27. How accurate is
Erdem S; Simsek DH; Degirmenci E; Aydin R; Bagbudar S; Ozluk Y; Sanli Y; Sanli O; Ozcan F
Urol Oncol; 2022 Jan; 40(1):6.e1-6.e9. PubMed ID: 34400066
[TBL] [Abstract][Full Text] [Related]
28. A Pilot Study of
Duan H; Ghanouni P; Daniel B; Rosenberg J; Thong A; Kunder C; Aparici CM; Davidzon GA; Moradi F; Sonn GA; Iagaru A
J Nucl Med; 2023 May; 64(5):744-750. PubMed ID: 36396456
[TBL] [Abstract][Full Text] [Related]
29.
De Man K; Van Laeken N; Schelfhout V; Fendler WP; Lambert B; Kersemans K; Piron S; Lumen N; Decaestecker K; Fonteyne V; Delrue L; De Vos F; Ost P
Eur Urol; 2022 Nov; 82(5):501-509. PubMed ID: 35690515
[TBL] [Abstract][Full Text] [Related]
30.
Fendler WP; Calais J; Allen-Auerbach M; Bluemel C; Eberhardt N; Emmett L; Gupta P; Hartenbach M; Hope TA; Okamoto S; Pfob CH; Pöppel TD; Rischpler C; Schwarzenböck S; Stebner V; Unterrainer M; Zacho HD; Maurer T; Gratzke C; Crispin A; Czernin J; Herrmann K; Eiber M
J Nucl Med; 2017 Oct; 58(10):1617-1623. PubMed ID: 28408531
[TBL] [Abstract][Full Text] [Related]
31. Comparison of
Schollhammer R; Robert G; Asselineau J; Yacoub M; Vimont D; Balamoutoff N; Bladou F; Bénard A; Hindié E; Gallerande HC; Morgat C
J Nucl Med; 2023 Mar; 64(3):379-385. PubMed ID: 36215569
[TBL] [Abstract][Full Text] [Related]
32. Synthesis and in vitro proof-of-concept studies on bispecific iron oxide magnetic nanoparticles targeting PSMA and GRP receptors for PET/MR imaging of prostate cancer.
Liolios C; Koutsikou TS; Salvanou EA; Kapiris F; Machairas E; Stampolaki M; Kolocouris A; Efthimiadou EΚ; Bouziotis P
Int J Pharm; 2022 Aug; 624():122008. PubMed ID: 35820513
[TBL] [Abstract][Full Text] [Related]
33. Clinical Translation of a Dual Integrin αvβ3- and Gastrin-Releasing Peptide Receptor-Targeting PET Radiotracer, 68Ga-BBN-RGD.
Zhang J; Niu G; Lang L; Li F; Fan X; Yan X; Yao S; Yan W; Huo L; Chen L; Li Z; Zhu Z; Chen X
J Nucl Med; 2017 Feb; 58(2):228-234. PubMed ID: 27493267
[TBL] [Abstract][Full Text] [Related]
34. Synthesis and biological evaluation of copper-64 radiolabeled [DUPA-6-Ahx-(NODAGA)-5-Ava-BBN(7-14)NH2], a novel bivalent targeting vector having affinity for two distinct biomarkers (GRPr/PSMA) of prostate cancer.
Bandari RP; Jiang Z; Reynolds TS; Bernskoetter NE; Szczodroski AF; Bassuner KJ; Kirkpatrick DL; Rold TL; Sieckman GL; Hoffman TJ; Connors JP; Smith CJ
Nucl Med Biol; 2014 Apr; 41(4):355-63. PubMed ID: 24508213
[TBL] [Abstract][Full Text] [Related]
35. Impact of uptake time on image quality of [
van der Sar ECA; Viol SLM; Braat AJAT; van Rooij R; Lam MGEH; de Jong HWAM; de Keizer B
Med Phys; 2023 Dec; 50(12):7619-7628. PubMed ID: 37093883
[TBL] [Abstract][Full Text] [Related]
36.
Hamed MAG; Basha MAA; Ahmed H; Obaya AA; Afifi AHM; Abdelbary EH
Acad Radiol; 2019 Apr; 26(4):450-460. PubMed ID: 29935970
[TBL] [Abstract][Full Text] [Related]
37. A heterodimeric [RGD-Glu-[(64)Cu-NO2A]-6-Ahx-RM2] αvβ3/GRPr-targeting antagonist radiotracer for PET imaging of prostate tumors.
Durkan K; Jiang Z; Rold TL; Sieckman GL; Hoffman TJ; Bandari RP; Szczodroski AF; Liu L; Miao Y; Reynolds TS; Smith CJ
Nucl Med Biol; 2014 Feb; 41(2):133-9. PubMed ID: 24480266
[TBL] [Abstract][Full Text] [Related]
38. Head-to-Head Comparison of
Sonni I; Felker ER; Lenis AT; Sisk AE; Bahri S; Allen-Auerbach M; Armstrong WR; Suvannarerg V; Tubtawee T; Grogan T; Elashoff D; Eiber M; Raman SS; Czernin J; Reiter RE; Calais J
J Nucl Med; 2022 Jun; 63(6):847-854. PubMed ID: 34649942
[TBL] [Abstract][Full Text] [Related]
39. Preclinical Study on GRPR-Targeted (68)Ga-Probes for PET Imaging of Prostate Cancer.
Sun Y; Ma X; Zhang Z; Sun Z; Loft M; Ding B; Liu C; Xu L; Yang M; Jiang Y; Liu J; Xiao Y; Cheng Z; Hong X
Bioconjug Chem; 2016 Aug; 27(8):1857-64. PubMed ID: 27399868
[TBL] [Abstract][Full Text] [Related]
40. Accuracy of [
Fassbender TF; Schiller F; Mix M; Maecke HR; Kiefer S; Drendel V; Meyer PT; Jilg CA
Nucl Med Biol; 2019 Mar; 70():32-38. PubMed ID: 30836254
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]